The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, inhalation anthrax, hepatitis C and cancer.
14200 Shady Grove Road
Maryland, United States
|2006-06-12||Cogenesys||Series A||$55M||New Enterprise Associates, OrbiMed Advisors, and Red Abbey Venture Partners|
|gera Therapeutics||Other Investors||Canadian Medical Discoveries Fund, Coller Capital, Desjardins, FondAction CSN, GeneChem Management, Lumira Capital, Medtech Partners, Multiple Capital, Neuroscience Partners, T2C2 Capital, and VenGrowth Capital Partners|